肺癌的免疫治疗
| 作者: |
1陈东方,
1钟润波
1 上海交通大学附属胸科医院呼吸内科，上海 200030 |
| 通讯: |
钟润波
Email: 13761156937@139.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.01.028 |
| 基金: | 上海市胸科医院科技发展基金重大重点项目(2014YZDC20700)。 |
摘要
近年来，免疫治疗已成为晚期肺癌新的研究方向。其中免疫检查点抑制药的重要性凸显，主要包括细胞毒性T淋巴细胞相关抗原4抑制药与程序性细胞死亡蛋白-1及其配体(PD-L1)抑制药，尤其是后者已在晚期非小细胞肺癌一线及二线治疗中取得了突破性进展。
关键词：
肺癌；免疫治疗；免疫检查点抑制药；疗效预测标志物；进展
Immunotherapy of lung cancer
CorrespondingAuthor: ZHONG Runbo Email: 13761156937@139.com
DOI: 10.3978/j.issn.2095-6959.2018.01.028
Foundation: This work was supported by Shanghai Chest Hospital Key Project, China (2014YZDC20700).
Abstract
In recent years, immunotherapy has become a new research direction of lung cancer. Immune checkpoint inhibitors (ICIs) including cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors are becoming more and more important, which have achieved a success in the first-line or second-line treatment for non-small cell lung cancer.
Keywords：
lung cancer; immunotherapy; immune checkpoint inhibitors; predictive marker; progression